Literature DB >> 15474371

M1 muscarinic receptor activation protects neurons from beta-amyloid toxicity. A role for Wnt signaling pathway.

Ginny G Farías1, Juan A Godoy, Félix Hernández, Jesús Avila, Abraham Fisher, Nibaldo C Inestrosa.   

Abstract

Amyloid-beta-peptide (Abeta) deposits are one of the hallmark features of Alzheimer's disease. Signal transduction alterations are implicate in the neuronal responses to Abeta, which include neurotransmitter systems and pathways involved in the maintenance of the nervous system. In this context, we have recently found that Abeta-neurotoxicity triggers a loss of Wnt signaling. We report here that M1-acetylcholine-muscarinic-receptor (mAChR) activation protects neurons from Abeta-toxicity. Concomitant with this effect, a modulation of the Wnt signaling was observed. M1 mAChR activation inhibits glycogen-synthase-kinase-3beta (GSK-3beta) activity, stabilizes cytoplasmic and nuclear beta-catenin, and induces the expression of the Wnt target genes engrailed and cyclin-D1, reverting the switch off of the Wnt pathway caused by Abeta-toxicity. Neurons from mice that overexpress GSK-3beta allow us to establish that M1 mAChR stimulation leads to GSK-3beta inactivation. We conclude that the cross-talk between the muscarinic signaling and Wnt components underlie the neuroprotective effect of the M1 mAChR activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15474371     DOI: 10.1016/j.nbd.2004.07.016

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  25 in total

Review 1.  Wnt signaling: role in Alzheimer disease and schizophrenia.

Authors:  Nibaldo C Inestrosa; Carla Montecinos-Oliva; Marco Fuenzalida
Journal:  J Neuroimmune Pharmacol       Date:  2012-11-18       Impact factor: 4.147

2.  Inhibition of ligand binding to G protein-coupled receptors by arachidonic acid.

Authors:  Elizabeth Z Bordayo; John R Fawcett; Sarita Lagalwar; Aleta L Svitak; William H Frey
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

3.  MHP-133, a drug with multiple CNS targets: potential for neuroprotection and enhanced cognition.

Authors:  Jerry J Buccafusco; James C Powers; Maria A Hernandez; Mark A Prendergast; Alvin V Terry; Ramamohana R Jonnala
Journal:  Neurochem Res       Date:  2007-04-03       Impact factor: 3.996

Review 4.  Wnt and lithium: a common destiny in the therapy of nervous system pathologies?

Authors:  Delphine Meffre; Julien Grenier; Sophie Bernard; Françoise Courtin; Todor Dudev; Ghjuvan'Ghjacumu Shackleford; Mehrnaz Jafarian-Tehrani; Charbel Massaad
Journal:  Cell Mol Life Sci       Date:  2013-06-09       Impact factor: 9.261

Review 5.  Role of β-catenin/TCF-4 signaling in HIV replication and pathogenesis: insights to informing novel anti-HIV molecular therapeutics.

Authors:  Lisa J Henderson; Lena Al-Harthi
Journal:  J Neuroimmune Pharmacol       Date:  2011-03-08       Impact factor: 4.147

Review 6.  LRP5 and LRP6 in development and disease.

Authors:  Danese M Joiner; Jiyuan Ke; Zhendong Zhong; H Eric Xu; Bart O Williams
Journal:  Trends Endocrinol Metab       Date:  2013-01       Impact factor: 12.015

Review 7.  Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

Authors:  Abraham Fisher
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

8.  Activation of muscarinic receptors inhibits glutamate-induced GSK-3β overactivation in PC12 cells.

Authors:  Ke Ma; Li-min Yang; Hong-zhuan Chen; Yang Lu
Journal:  Acta Pharmacol Sin       Date:  2013-05-20       Impact factor: 6.150

9.  To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease.

Authors:  Breno Satler Diniz; Jony Arrais Pinto; Maria Luiza Cavichioli Gonzaga; Fabiana Meira Guimarães; Wagner Farid Gattaz; Orestes Vicente Forlenza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-02-17       Impact factor: 5.270

Review 10.  M1 muscarinic acetylcholine receptor in Alzheimer's disease.

Authors:  Shangtong Jiang; Yanfang Li; Cuilin Zhang; Yingjun Zhao; Guojun Bu; Huaxi Xu; Yun-Wu Zhang
Journal:  Neurosci Bull       Date:  2014-03-03       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.